Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
41 hedge funds and large institutions have $274M invested in Dicerna Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 14 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2% less funds holding
Funds holding: 42 → 41 (-1)
21% less capital invested
Capital invested by funds: $349M → $274M (-$74.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.84M |
| 2 |
JP Morgan Chase
New York
|
+$1.68M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.4M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.16M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.88M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.97M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.45M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$2.23M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WSA
51
Wall Street Associates
Lajolla,
California
| – | -$322K | -11,400 | Closed |
|
52
Goldman Sachs
New York
| – | -$256K | -9,079 | Closed |
|
|
FAM
53
Fred Alger Management
New York
| – | -$153K | -5,400 | Closed |
|
|
MAA
54
Managed Account Advisors
Jersey City,
New Jersey
| – | -$3K | -99 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | +$181 | +10 | New |
|
DRNA Hedge Fund Activity: Q2 2014 in Review
41 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2014, worth a combined $274M — down 21% from $349M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DRNA and 13 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 13 added.
The largest buyer was Sabby Management, adding an estimated $1.84M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $4.88M sold.
- 41 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2014, down from 42 in Q1 2014.
- Funds reported $274M of Dicerna Pharmaceuticals, Inc. stock for Q2 2014, down 21% quarter-over-quarter.
- 13 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2014 and 14 closed out, a net change of -1 holder.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2014 was Sabby Management, an estimated $1.84M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2014 was T. Rowe Price Associates, an estimated $4.88M sold.
Based on aggregated 13F filings for Q2 2014.